TY - JOUR
T1 - The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells
AU - Gallo, Marianna
AU - De Luca, Antonella
AU - Frezzetti, Daniela
AU - Passaro, Valeria
AU - Maiello, Monica R.
AU - Normanno, Nicola
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction: Circulating tumor cell (CTC) counts represent an attractive strategy for monitoring response to therapy in patients with advanced non-small cell lung cancer (NSCLC). Changes in the CTCs number during the treatment have been proposed as a predictive biomarker of response to both chemotherapy and targeted therapies. Profiling of CTCs might also allow the assessment of the dynamics of predictive biomarkers such as EGFR, ALK, ROS1, and PD-L1, and provide relevant information in patients progressing on treatment with targeted agents including immunotherapeutics. Areas covered: A search of peer-reviewed literature in bibliographic databases was undertaken to discuss studies on CTCs and their predictive role in NSCLC. Expert opinion: To date, some challenges limit the clinical utility of CTCs in monitoring the response to treatment in NSCLC. The standardization of techniques for CTCs isolation and characterization and their validation on larger cohorts of patients might help to translate CTCs analysis in the clinic. However, studies on CTCs can provide information on molecular mechanisms involved in NSCLC progression and in the acquired resistance to treatments.
AB - Introduction: Circulating tumor cell (CTC) counts represent an attractive strategy for monitoring response to therapy in patients with advanced non-small cell lung cancer (NSCLC). Changes in the CTCs number during the treatment have been proposed as a predictive biomarker of response to both chemotherapy and targeted therapies. Profiling of CTCs might also allow the assessment of the dynamics of predictive biomarkers such as EGFR, ALK, ROS1, and PD-L1, and provide relevant information in patients progressing on treatment with targeted agents including immunotherapeutics. Areas covered: A search of peer-reviewed literature in bibliographic databases was undertaken to discuss studies on CTCs and their predictive role in NSCLC. Expert opinion: To date, some challenges limit the clinical utility of CTCs in monitoring the response to treatment in NSCLC. The standardization of techniques for CTCs isolation and characterization and their validation on larger cohorts of patients might help to translate CTCs analysis in the clinic. However, studies on CTCs can provide information on molecular mechanisms involved in NSCLC progression and in the acquired resistance to treatments.
KW - biomarkers
KW - chemotherapy
KW - Circulating tumor cells
KW - non-small-cell lung cancer
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85071631830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071631830&partnerID=8YFLogxK
U2 - 10.1080/14737159.2019.1640606
DO - 10.1080/14737159.2019.1640606
M3 - Review article
C2 - 31305173
AN - SCOPUS:85071631830
VL - 19
SP - 683
EP - 694
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 8
ER -